Document Detail


Correlation of CX3CL1 and CX3CR1 levels with response to infliximab therapy in patients with rheumatoid arthritis.
MedLine Citation:
PMID:  19369458     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To examine the relation between serum chemokine levels and patient responsiveness to infliximab, and the influence of infliximab administration on serum chemokine levels. METHODS: Serum levels of the chemokines CX3CL1, CXCL8, CCL3, and CXCL10 were quantified prior to (at baseline) and after 30 weeks of treatment with infliximab in 20 patients using enzyme-linked immunosorbent assays. Disease status was assessed using the Disease Activity Score (DAS28). The response to infliximab was classified according to the European League Against Rheumatism (EULAR) response criteria. RESULTS: By 30 weeks, infliximab produced a significant overall reduction in DAS28 among the 20 patients with RA, although only 12 achieved a good to moderate response based on EULAR response criteria. A significant reduction in CX3CL1 was seen in the responsive group, although infliximab treatment had no significant effect on the serum levels of the other 3 chemokines. Comparison of patients with lower (<2000 pg/ml) and higher (>or=2000 pg/ml) basal CX3CL1 levels revealed that DAS28, erythrocyte sedimentation rate, C-reactive protein, and CX3CL1 levels were all significantly diminished by infliximab in RA patients with lower basal CX3CL1 levels, but not in those with higher basal levels. In addition, cell-surface expression of CX3CR1 protein in peripheral blood CD8+CD3+ T cells and mRNA expression of CX3CR1 in lymphocytes were both significantly downregulated after infliximab treatment in the responsive group. CONCLUSION: Our results suggest that the CX3CL1-CX3CR1 system in patients with active RA may be sensitive to anti-tumor necrosis factor-alpha therapy, and confirm that CX3CL1 plays a crucial role in the pathogenesis of RA.
Authors:
Tsuyoshi Odai; Mizuho Matsunawa; Ryo Takahashi; Kuninobu Wakabayashi; Takeo Isozaki; Nobuyuki Yajima; Yusuke Miwa; Tsuyoshi Kasama
Related Documents :
16357708 - Audiovestibular disorders in patients with ankylosing spondylitis.
17143978 - The association of rheumatoid arthritis and its treatment with sinus disease.
9562658 - Importance of reactive oxygen species in rheumatoid arthritis.
19602788 - Inflammatory cells in lung disease associated with rheumatoid arthritis.
6971388 - Serological findings in patients with "ana-negative" systemic lupus erythematosus.
24966468 - Abnormal cytokine profile in patients with obstructive sleep apnea-hypopnea syndrome an...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-04-15
Journal Detail:
Title:  The Journal of rheumatology     Volume:  36     ISSN:  0315-162X     ISO Abbreviation:  J. Rheumatol.     Publication Date:  2009 Jun 
Date Detail:
Created Date:  2009-06-10     Completed Date:  2009-08-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7501984     Medline TA:  J Rheumatol     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  1158-65     Citation Subset:  IM    
Affiliation:
Division of Rheumatology, Department of Internal Medicine, Showa University School of Medicine, Tokyo, 142-8666, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal / therapeutic use*
Antirheumatic Agents / therapeutic use*
Arthritis, Rheumatoid / blood*,  drug therapy*,  physiopathology
Chemokine CX3CL1 / blood*
Disability Evaluation
Female
Health Status
Humans
Male
Middle Aged
Receptors, Chemokine / blood*
Severity of Illness Index
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antirheumatic Agents; 0/CX3CL1 protein, human; 0/CX3CR1 protein, human; 0/Chemokine CX3CL1; 0/Receptors, Chemokine; 0/infliximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Serum urate during acute gout.
Next Document:  Validating and assessing the sensitivity of the Health Assessment Questionnaire-Disability Index-der...